BioCentury | Jan 9, 2019
Distillery Therapeutics

Endocrine/metabolic

...diabetes and have the product in Phase III testing for heart failure. Astellas Pharma Inc., Kotobuki Pharmaceutical Co....
BioCentury | Jan 3, 2019
Distillery Therapeutics

Cancer

...product in Phase III testing as an adjuvant for liver cancer. Astellas Pharma Inc. and Kotobuki Pharmaceutical Co....
BioCentury | Dec 15, 2016
Targets & Mechanisms

Keeping the Gas off AXL

...Intelligence Modality Company Product Description Indication Phase of development Small molecules Astellas Pharma Inc. (Tokyo:4503); Kotobuki Pharmaceutical Co....
BioCentury | Dec 10, 2016
Product Development

AML advances

...Molecular subtype Phase Treatment Response rate (A) Overall survival (mos.) Astellas Pharma Inc. (Tokyo:4503) / Kotobuki Pharmaceutical Co....
BioCentury | Nov 9, 2015
Clinical News

Gilteritinib: Phase III started

...etoposide and intermediate-dose cytarabine (MEC); and fludarabine, cytarabine and G-CSF with idarubicin (FLAG-IDA). Astellas and Kotobuki...
...exclusive, worldwide rights to develop and commercialize the product. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Kotobuki Pharmaceutical Co....
BioCentury | Apr 28, 2014
Company News

Astellas, Kotobuki, Merck sales and marketing update

...Astellas and Merck's MSD K.K. subsidiary announced the partners along with Kotobuki launched Suglat ipragliflozin in...
...the indication in the country. Astellas will manufacture and sell Suglat and co-promote it with Kotobuki...
..."comprehensive consideration of intensified competition" for the diabetes product. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Kotobuki Pharmaceutical Co....
BioCentury | Jan 20, 2014
Clinical News

Suglat ipragliflozin regulatory update

...2 (SGLT2) inhibitor approved for the indication in Japan. Astellas co-developed Suglat with Kotobuki. Astellas, Kotobuki...
..."comprehensive consideration of intensified competition" for the diabetes product. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Kotobuki Pharmaceutical Co....
BioCentury | Jan 18, 2014
Company News

Astellas' ipragliflozin approved in Japan

...inhibitor approved for the indication in Japan. Astellas co-developed Suglat with Kotobuki Pharmaceutical Co. (Tokyo, Japan). Astellas, Kotobuki...
BioCentury | May 6, 2013
Strategy

Doubling down in diabetes

...Taisho Pharmaceutical Holdings Co. Ltd. , and ipragliflozin in Japan from Astellas Pharma Inc. and Kotobuki Pharmaceutical Co....
...Duesseldorf, Germany Geisinger Health System , Danville, Pa. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Kotobuki Pharmaceutical Co....
BioCentury | Apr 15, 2013
Company News

Kotobuki, Shionogi deal

...Kotobuki granted Shionogi exclusive, worldwide rights to develop and commercialize cholesterol absorption inhibitor KT6-971 . Kotobuki...
...payment and is eligible for milestones and royalties. Shionogi declined to disclose financial details, while Kotobuki...
...dyslipidemia. Shionogi plans to start a Phase IIb trial by March 2013 for the indication. Kotobuki Pharmaceutical Co....
Items per page:
1 - 10 of 26
BioCentury | Jan 9, 2019
Distillery Therapeutics

Endocrine/metabolic

...diabetes and have the product in Phase III testing for heart failure. Astellas Pharma Inc., Kotobuki Pharmaceutical Co....
BioCentury | Jan 3, 2019
Distillery Therapeutics

Cancer

...product in Phase III testing as an adjuvant for liver cancer. Astellas Pharma Inc. and Kotobuki Pharmaceutical Co....
BioCentury | Dec 15, 2016
Targets & Mechanisms

Keeping the Gas off AXL

...Intelligence Modality Company Product Description Indication Phase of development Small molecules Astellas Pharma Inc. (Tokyo:4503); Kotobuki Pharmaceutical Co....
BioCentury | Dec 10, 2016
Product Development

AML advances

...Molecular subtype Phase Treatment Response rate (A) Overall survival (mos.) Astellas Pharma Inc. (Tokyo:4503) / Kotobuki Pharmaceutical Co....
BioCentury | Nov 9, 2015
Clinical News

Gilteritinib: Phase III started

...etoposide and intermediate-dose cytarabine (MEC); and fludarabine, cytarabine and G-CSF with idarubicin (FLAG-IDA). Astellas and Kotobuki...
...exclusive, worldwide rights to develop and commercialize the product. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Kotobuki Pharmaceutical Co....
BioCentury | Apr 28, 2014
Company News

Astellas, Kotobuki, Merck sales and marketing update

...Astellas and Merck's MSD K.K. subsidiary announced the partners along with Kotobuki launched Suglat ipragliflozin in...
...the indication in the country. Astellas will manufacture and sell Suglat and co-promote it with Kotobuki...
..."comprehensive consideration of intensified competition" for the diabetes product. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Kotobuki Pharmaceutical Co....
BioCentury | Jan 20, 2014
Clinical News

Suglat ipragliflozin regulatory update

...2 (SGLT2) inhibitor approved for the indication in Japan. Astellas co-developed Suglat with Kotobuki. Astellas, Kotobuki...
..."comprehensive consideration of intensified competition" for the diabetes product. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Kotobuki Pharmaceutical Co....
BioCentury | Jan 18, 2014
Company News

Astellas' ipragliflozin approved in Japan

...inhibitor approved for the indication in Japan. Astellas co-developed Suglat with Kotobuki Pharmaceutical Co. (Tokyo, Japan). Astellas, Kotobuki...
BioCentury | May 6, 2013
Strategy

Doubling down in diabetes

...Taisho Pharmaceutical Holdings Co. Ltd. , and ipragliflozin in Japan from Astellas Pharma Inc. and Kotobuki Pharmaceutical Co....
...Duesseldorf, Germany Geisinger Health System , Danville, Pa. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Kotobuki Pharmaceutical Co....
BioCentury | Apr 15, 2013
Company News

Kotobuki, Shionogi deal

...Kotobuki granted Shionogi exclusive, worldwide rights to develop and commercialize cholesterol absorption inhibitor KT6-971 . Kotobuki...
...payment and is eligible for milestones and royalties. Shionogi declined to disclose financial details, while Kotobuki...
...dyslipidemia. Shionogi plans to start a Phase IIb trial by March 2013 for the indication. Kotobuki Pharmaceutical Co....
Items per page:
1 - 10 of 26